Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II-III peri- and post-operative chemotherapy in resectable pancreatic carcinoma
2010-019942-23Phase 2Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Sep 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cisplatin, epirubicin, capecitabine and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Event-free rate at 1 year. Started Sep 2010; status: completed.
02
Drugs
cisplatinepirubicincapecitabinegemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-019942-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019942-23.